Atrial fibrillation for internists: current practice
Open Access
- 22 March 2020
- journal article
- review article
- Published by SMW Supporting Association in Swiss Medical Weekly
- Vol. 150, w20196
- https://doi.org/10.4414/smw.2020.20196
Abstract
Atrial fibrillation (AF) has become a global epidemic and puts affected patients at high risk of adverse events. In this review we summarise the current evidence on risk factors and complications of AF, describe current treatment strategies, and outline new fields of research. Current evidence shows that hypertension and obesity are the two most important modifiable risk factors for the development of AF. Patients with AF face an increased stroke risk. Oral anticoagulation reduces this risk substantially. Mainly for reasons of safety and ease of use, non-vitamin K antagonist oral anticoagulants are preferred for stroke prevention. Rate and rhythm control interventions remain important and are mainly used for symptom control in AF patients. Rate control is recommended as an initial treatment and in patients with a low or absent symptom burden. Following the advent of AF ablation 20 years ago, the chances of successful sustained rhythm control have increased. Nevertheless, the procedural risks, although low, must be discussed with the patient in the context of the potential benefits. Heart failure and AF often coexist, which creates a further challenge for optimal AF management. Recent studies have shown that AF patients have a high burden of silent brain lesions, and that these lesions are associated with cognitive dysfunction. A better understanding of these interrelationships may eventually help the development of new prevention and treatment strategies to decrease the burden and complications associated with AF.This publication has 83 references indexed in Scilit:
- Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trialThe Lancet, 2012
- Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure: Results From the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) StudyJournal of the American College of Cardiology, 2012
- Risk of Death and Cardiovascular Events in Initially Healthy Women With New-Onset Atrial FibrillationJAMA, 2011
- Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk FactorsCirculation, 2011
- The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation: The WHS (Women's Health Study)Journal of the American College of Cardiology, 2010
- Relation of Vigorous Exercise to Risk of Atrial FibrillationThe American Journal of Cardiology, 2009
- Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in WomenCirculation, 2009
- Physical Activity and Incidence of Atrial Fibrillation in Older AdultsCirculation, 2008
- Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programAmerican Heart Journal, 2006
- Analysis of Current Management of Atrial Fibrillation in the Acute Setting: GEFAUR-1 StudyAnnals of Emergency Medicine, 2005